{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:01:42Z","timestamp":1787166102900,"version":"build-2736575974"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2022,2]]},"abstract":"Abstract<\/jats:title>\n \n Background and Aim<\/jats:title>\n In 2017, ustekinumab (UST) was included in Israel's National Basket of Health Services for treatment of biologic\u2010experienced Crohn's disease (CD) patients with moderately to severely active disease. This study aims to provide real\u2010world evidence on persistence and clinical outcomes among early users of UST.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study was conducted using data from Maccabi Healthcare Services (MHS; 2.5\u2010million\u2010member state\u2010mandated health provider, Israel). Adult patients with a CD diagnosis code who had \u22651 dispensed UST prescription in 2017\u20132018 and at least 12\u2009months of prior continuous health plan enrollment were included. Outcomes, including treatment discontinuation, dose\u2010escalation (based on shortened intervals between purchases), CD\u2010related surgery, CD\u2010related hospitalization, corticosteroid (CS) discontinuation, and use of opioids were evaluated from the date of first dispensed UST through the end of 2019 using Kaplan\u2013Meier analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 162 eligible patients (81 [49.4%] female; median age 34.4\u2009years [IQR 23.2\u201346.3]; median years since CD diagnosis 8.6 [IQR 4\u00b78\u201316.0]) were enrolled in the study. Discontinuation rate after 365 and 540\u2009days of follow\u2010up was 27.8% and 35.6%. Dose escalation was estimated at 15.4% and 28.6%, respectively. The first\u2010year cumulative rate of CD\u2010related surgery and CD\u2010related hospitalization were estimated at 4.7% and 9.8%, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this real\u2010world CD cohort of UST users, results suggest persistence is relatively high as compared to other biologics for CD. Comparative effectiveness of different biologic treatments for CD in this population should be further explored.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jgh3.12670","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T03:38:42Z","timestamp":1643168322000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real\u2010world data analysis"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-4161","authenticated-orcid":false,"given":"Tamar","family":"Banon","sequence":"first","affiliation":[{"name":"Maccabitech Maccabi Institute for Research & Innovation Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Weil","sequence":"additional","affiliation":[{"name":"Maccabitech Maccabi Institute for Research & Innovation Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Borsi","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Ltd High Wycombe UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[{"name":"Maccabitech Maccabi Institute for Research & Innovation Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehavi","family":"Shakked","sequence":"additional","affiliation":[{"name":"Janssen Israel Kibbutz Shefayim Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Barit Ben\u2010David","sequence":"additional","affiliation":[{"name":"Janssen Israel Kibbutz Shefayim Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.34"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.909"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12727"},{"key":"e_1_2_6_5_1","unstructured":"European Commission Approves Stelara\u00ae[Ustekinumab] for treatment of adults with moderately to severely active Crohn's disease [press release].2016."},{"key":"e_1_2_6_6_1","unstructured":"Israel Centeral Bureau of Statistics. 1995 Census of Population and Housing Jerusalem; 1998.http:\/\/www1.cbs.gov.il\/census\/"},{"key":"e_1_2_6_7_1","unstructured":"WHO.BMI Classification.2006. Cited 2014. Available from URL:http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:EJEP.0000006635.36802.c8"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.08.002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6634"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03718"},{"key":"e_1_2_6_12_1","volume-title":"Israel National Cancer Registry","author":"Israel Center for Disease Control","year":"1982"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1624817"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01276-3"}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jgh3.12670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T07:22:13Z","timestamp":1693120933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.12670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/jgh3.12670"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.12670","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"value":"2397-9070","type":"print"},{"value":"2397-9070","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"2021-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}